Evidence map›Paper›PMID 41876621›Full record

ArticleScientific reports2026

Spirohydantoin derivatives exert dopamine D

Katarzyna Kucwaj-Brysz, Sabina Podlewska, Klaudia Jakubowska, Aleksandra Mąsior, Michał Wilczkowski, Beata Duszyńska, Justyna Drukała, Jadwiga Handzlik, Danuta Jantas

Abstract read
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Katarzyna Kucwaj-BryszChair of Chemical Technology and Biotechnology of Drugs, Jagiellonian University Medical College, Medyczna 9, 30-688, Cracow, Poland. katarzyna.kucwaj@uj.edu.pl.
Sabina PodlewskaMaj Institute of Pharmacology, Polish Academy of Sciences, Smetna 12, 31-343, Cracow, Poland.
Klaudia JakubowskaMaj Institute of Pharmacology, Polish Academy of Sciences, Smetna 12, 31-343, Cracow, Poland.
Aleksandra MąsiorMaj Institute of Pharmacology, Polish Academy of Sciences, Smetna 12, 31-343, Cracow, Poland.
Michał WilczkowskiMaj Institute of Pharmacology, Polish Academy of Sciences, Smetna 12, 31-343, Cracow, Poland.
Beata DuszyńskaMaj Institute of Pharmacology, Polish Academy of Sciences, Smetna 12, 31-343, Cracow, Poland.
Justyna DrukałaDepartment of Cell Biology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Gronostajowa 7, 30-387, Cracow, Poland.
Jadwiga HandzlikChair of Chemical Technology and Biotechnology of Drugs, Jagiellonian University Medical College, Medyczna 9, 30-688, Cracow, Poland.
Danuta JantasMaj Institute of Pharmacology, Polish Academy of Sciences, Smetna 12, 31-343, Cracow, Poland. jantas@if-pan.krakow.pl.

Funding

The National Science Centre and statutory funds of Maj Institute of Pharmacology Polish Academy of Sciences. 2021/43/D/NZ7/00891
6 · The paper itself

Abstract

Glioblastoma multiforme (GBM) maintains one of the most aggressive brain tumor with increasing resistance. Herein in vitro study investigates spirohydantoin derivatives with diversified dopamine D

Indexed as

Antineoplastic AgentsBrain NeoplasmsCalpainGlioblastomaHydantoinsReceptors, Dopamine D2Spiro CompoundsCell Line, TumorHumansMolecular Docking SimulationTemozolomideAntineoplastic AgentsCalpainHydantoinsReceptors, Dopamine D2Spiro CompoundsTemozolomideA172Calpain inhibitorsDopamine receptors’ ligandsGlioblastoma multiformeU138MGU87MG

Identifiers

PMID41876621
PMCPMC13168489

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.